(Q43153223)

14 November 2017

Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. (English)

1 reference

14 November 2017

1 reference

1 reference

1 reference

4

1 reference

14 November 2017

Markus Klinger

1

1 reference

14 November 2017

Dietmar Tamandl

2

1 reference

14 November 2017

Sandra Eipeldauer

3

1 reference

14 November 2017

Beata Herberger

5

1 reference

14 November 2017

Klaus Kaczirek

6

1 reference

14 November 2017

Marion Dorfmeister

7

1 reference

14 November 2017

Birgit Gruenberger

8

1 reference

14 November 2017

Thomas Gruenberger

9

1 reference

14 November 2017

language of work or name

1 reference

23 February 2010

1 reference

Annals of Surgical Oncology

14 November 2017

1 reference

14 November 2017

17

1 reference

14 November 2017

8

1 reference

14 November 2017

2059-2065

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-010-0972-9

14 November 2017

0 references

cites work

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-0972-9

Crossref

reference URL

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-010-0972-9

Crossref

reference URL

10.1245/S10434-010-0972-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference